GenMark Diagnostics (NASDAQ:GNMK) expects Q2 sales to be ~$40.1M, up 118% Y/Y, as COVID-19 impacted second quarter placements and revenue.
During the quarter, the company placed net 71 ePlex analyzers (+48%) and expects ePlex revenue to be ~$35.2M (+195%). SARS-CoV-2 consumables accounted for ~48% of total ePlex revenue
The company will release final Q2 results in early August.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.